Amedeo Smart

Free Medical Literature Service

 

Amedeo

Colorectal Neoplasms
  Free Subscription

Articles published in
Br J Cancer
    October 2025
  1. OSTERMAN E, Syriopoulou E, Martling A, Andersson TM, et al
    Impact of socioeconomics on recurrences and survival in non-metastasized colorectal cancer.
    Br J Cancer. 2025 Oct 4. doi: 10.1038/s41416-025-03224.
    >> Share

  2. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
    Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
    Br J Cancer. 2025;133:874-885.
    >> Share

  3. THONG MSY, Doege D, Koch-Gallenkamp L, Bertram H, et al
    Fatigue in long-term cancer survivors: prevalence, associated factors, and mortality. A prospective population-based study.
    Br J Cancer. 2025;133:831-843.
    >> Share

  4. YU H, Jin S, Zeng M, Yang Z, et al
    TIGIT antibody with PVR competitive ability enhances cancer immunotherapy and capable of eliciting anti-tumour immune memory.
    Br J Cancer. 2025;133:743-755.
    >> Share

  5. HOPPENER DJ, Verheul SML, Nierop PMH, Buisman FE, et al
    The colorectal liver metastasis growth pattern phenotype is not dependent on genotype.
    Br J Cancer. 2025;133:945-955.
    >> Share

    September 2025
  6. XIE W, Luo Q, Ou Z, Liu W, et al
    An ABCC1-based risk model is effective in the diagnosis of synchronous peritoneal metastasis in advanced colorectal cancer.
    Br J Cancer. 2025 Sep 26. doi: 10.1038/s41416-025-03203.
    >> Share

  7. KAWAMURA H, Honda M, Nakayama Y, Oba K, et al
    Adverse events of postoperative adjuvant chemotherapy predict survival outcomes in locally advanced colorectal cancer: a pooled analysis of Japanese clinical trials.
    Br J Cancer. 2025 Sep 22. doi: 10.1038/s41416-025-03199.
    >> Share

  8. FENG Y, Zhu J, Ou C, Deng Z, et al
    Retraction Note: MicroRNA-145 inhibits tumour growth and metastasis in colorectal cancer by targeting fascin-1.
    Br J Cancer. 2025 Sep 19. doi: 10.1038/s41416-025-03209.
    >> Share

  9. MONTERO-CALLE A, Jimenez de Ocana S, Rejas-Gonzalez R, Benavente-Naranjo R, et al
    Deciphering the central role of TMOD2 in colorectal cancer progression and metastasis.
    Br J Cancer. 2025 Sep 17. doi: 10.1038/s41416-025-03184.
    >> Share

    August 2025
  10. BALLHAUSEN A, Morano F, Stahler A, Lonardi S, et al
    Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials.
    Br J Cancer. 2025 Aug 28. doi: 10.1038/s41416-025-03164.
    >> Share

  11. BARLOW M, Messenger D, Preece R, Prowse A, et al
    The diagnostic accuracy of the faecal immunochemical test for the detection of early-onset colorectal cancer: an age-stratified analysis in South West England.
    Br J Cancer. 2025 Aug 22. doi: 10.1038/s41416-025-03154.
    >> Share

  12. ZHANG D, Yang S, Xu H, Chen Z, et al
    The novel role of DUSP4 in suppressing ferroptosis and promoting cytotoxicity of CD8(+) T cells in MSI colorectal cancer.
    Br J Cancer. 2025 Aug 22. doi: 10.1038/s41416-025-03119.
    >> Share

  13. GALMARINI CM, Zamora R, Gomez Del Campo P, Del Castillo-Izquierdo J, et al
    PROCC: a predictive score to identify KRAS wild type metastatic colorectal cancer patients who are likely to obtain survival benefit from panitumumab treatment.
    Br J Cancer. 2025 Aug 20. doi: 10.1038/s41416-025-03157.
    >> Share

  14. TOH Y, Wu L, Tu J, Liang Z, et al
    Anti-tumor activity of camptothecin analog conjugate of an RSPO4-based peptibody targeting LGR4/5/6 in preclinical models of colorectal cancer.
    Br J Cancer. 2025 Aug 18. doi: 10.1038/s41416-025-03121.
    >> Share

    July 2025
  15. SHENG Y, Yan L, Liu Q, Peng Y, et al
    The pronounced cytotoxic effects of chimeric antigen receptor T cells targeting B7-H3 in organoids and liver xenografts derived from colorectal cancer patients.
    Br J Cancer. 2025 Jul 28. doi: 10.1038/s41416-025-03114.
    >> Share

  16. YU L, Guo Q, Gu X, Wang Z, et al
    Impact of gut microbiome on radiotherapy and immunotherapy efficacy in microsatellite-stable colorectal cancer: role of propionic acid and B. fragilis.
    Br J Cancer. 2025 Jul 26. doi: 10.1038/s41416-025-03105.
    >> Share

  17. ZHANG J, Xiao Z, Lai D, Sun J, et al
    Retraction Note: miR-21, miR-17 and miR-19a induced by phosphatase of regenerating liver-3 promote the proliferation and metastasis of colon cancer.
    Br J Cancer. 2025 Jul 25. doi: 10.1038/s41416-025-03135.
    >> Share

  18. ZHANG J, Dong H, Liang L, Hu L, et al
    Targeting gut microbiota and arginase boosts MEK inhibitors' enhancement of antitumour immunity via MHC-I upregulation in colorectal cancer.
    Br J Cancer. 2025 Jul 17. doi: 10.1038/s41416-025-03106.
    >> Share

  19. SEO JW, Kim JY, Ha YJ, Tak KH, et al
    Prognostic and therapeutic value of a 23-gene risk score tailored to the molecular characteristics of mucinous colorectal cancer.
    Br J Cancer. 2025 Jul 2. doi: 10.1038/s41416-025-03104.
    >> Share

    June 2025
  20. MESA-EGUIAGARAY I, Iakovliev A, Li X, Timofeeva M, et al
    Association between methylation quantitative trait loci and colorectal cancer risk, survival and cancer recurrence.
    Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03064.
    >> Share

  21. ZHONG W, Zhang Y, Wang W, Shao Z, et al
    TRIM26 deficiency potentially suppresses colorectal cancer liver metastasis through NF-kappaB-mediated M1-like tumor-associated macrophage polarization.
    Br J Cancer. 2025 Jun 9. doi: 10.1038/s41416-025-03072.
    >> Share

  22. RUBIO-CUESTA B, Carretero-Puche C, Llamas P, Sarmentero J, et al
    Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer.
    Br J Cancer. 2025 Jun 6. doi: 10.1038/s41416-025-03058.
    >> Share

  23. ANDEL D, Nouwens AJ, Klaassen S, Laoukili J, et al
    Rational design of alternative treatment options for radioresistant rectal cancer using patient-derived organoids.
    Br J Cancer. 2025;132:973-981.
    >> Share

    April 2025
  24. YUAN F, Jia G, Wen W, Xu S, et al
    Blood metabolic biomarkers and colorectal cancer risk: results from large prospective cohort and Mendelian randomisation analyses.
    Br J Cancer. 2025 Apr 30. doi: 10.1038/s41416-025-02997.
    >> Share

  25. REITSAM NG, Markl B
    Stroma AReactive Invasion Front Areas (SARIFA) and the tumour immune microenvironment in colorectal cancer.
    Br J Cancer. 2025 Apr 26. doi: 10.1038/s41416-025-03034.
    >> Share

  26. LEE HJ, Park SW, Lee JH, Chang SY, et al
    Correction: Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes.
    Br J Cancer. 2025 Apr 11. doi: 10.1038/s41416-025-02988.
    >> Share

  27. HASJIM BJ, Ostowari A, Gandawidjaja M, Mohammadi MD, et al
    De novo colorectal cancer after kidney transplantation: a systematic review and meta-analysis.
    Br J Cancer. 2025 Apr 5. doi: 10.1038/s41416-025-02994.
    >> Share

  28. ELOMAA H, Tarkiainen V, Aijala VK, Sirnio P, et al
    Associations of mucinous differentiation and mucin expression with immune cell infiltration and prognosis in colorectal adenocarcinoma.
    Br J Cancer. 2025;132:660-669.
    >> Share

    March 2025
  29. GRANCHER A, Beaussire-Trouvay L, Vernon V, Dutherage M, et al
    ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer.
    Br J Cancer. 2025 Mar 15. doi: 10.1038/s41416-025-02971.
    >> Share

  30. TANG F, Zhu Y, Shen J, Yuan B, et al
    CD44(+) cells enhance pro-tumor stroma in the spatial landscape of colorectal cancer leading edge.
    Br J Cancer. 2025 Mar 12. doi: 10.1038/s41416-025-02968.
    >> Share

  31. TAPIAINEN VV, Sirnio P, Elomaa H, Karjalainen H, et al
    Stroma AReactive Invasion Front Areas (SARIFA), tumour immune microenvironment, and survival in colorectal cancer.
    Br J Cancer. 2025 Mar 7. doi: 10.1038/s41416-025-02972.
    >> Share

  32. LEE HJ, Park SW, Lee JH, Chang SY, et al
    Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes.
    Br J Cancer. 2025 Mar 3. doi: 10.1038/s41416-025-02964.
    >> Share

    February 2025
  33. ZHANG Y, Wu D, Zhang Z, Ma J, et al
    Correction: Impact of lymph node metastasis on immune microenvironment and prognosis in colorectal cancer liver metastasis: insights from multiomics profiling.
    Br J Cancer. 2025 Feb 17. doi: 10.1038/s41416-025-02941.
    >> Share

  34. BUNDRED J, Lal N, Chan DKH, Buczacki SJA, et al
    Lymph node yield as a surrogate marker for tumour biology and prognosis in colon cancer.
    Br J Cancer. 2025 Feb 14. doi: 10.1038/s41416-025-02949.
    >> Share

  35. KATO Y, Seishima R, Hattori K, Kato H, et al
    Significance of homologous recombinant deficiency as a biomarker for drug sensitivity in colorectal cancer.
    Br J Cancer. 2025 Feb 11. doi: 10.1038/s41416-025-02950.
    >> Share

    January 2025
  36. ZHANG Y, Wu D, Zhang Z, Ma J, et al
    Impact of lymph node metastasis on immune microenvironment and prognosis in colorectal cancer liver metastasis: insights from multiomics profiling.
    Br J Cancer. 2025 Jan 3. doi: 10.1038/s41416-024-02921.
    >> Share

    December 2024
  37. LIU C, Reger M, Fan H, Wang J, et al
    Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
    >> Share

    November 2024
  38. PRETTA A, Ziranu P, Perissinotto E, Ghelardi F, et al
    Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenon.
    Br J Cancer. 2024 Nov 27. doi: 10.1038/s41416-024-02902.
    >> Share

  39. CHAN WC, Liu L, Bouras E, Zuber V, et al
    Associations of blood lipids and LDL cholesterol lowering drug-targets with colorectal cancer risk: a Mendelian randomisation study.
    Br J Cancer. 2024 Nov 23. doi: 10.1038/s41416-024-02900.
    >> Share

  40. POGHOSYAN S, Frenkel N, van den Bent L, Raats D, et al
    VEGF-C propagates 'onward' colorectal cancer metastasis from liver to lung.
    Br J Cancer. 2024 Nov 9. doi: 10.1038/s41416-024-02892.
    >> Share

  41. CAMPOS GUDINO R, Neudorf NM, Andromidas D, Lichtensztejn Z, et al
    Loss of EMI1 compromises chromosome stability and is associated with cellular transformation in colonic epithelial cell contexts.
    Br J Cancer. 2024;131:1516-1528.
    >> Share

    October 2024
  42. LI B, Yang W, Liu N, Bi D, et al
    Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a prospective single-center explorative study.
    Br J Cancer. 2024 Oct 24. doi: 10.1038/s41416-024-02885.
    >> Share

  43. OGAARD N, Jensen SO, Orntoft MW, Demuth C, et al
    Circulating tumour DNA and risk of recurrence in patients with asymptomatic versus symptomatic colorectal cancer.
    Br J Cancer. 2024 Oct 10. doi: 10.1038/s41416-024-02867.
    >> Share

  44. NOH H, Lee J, Seyed Khoei N, Peruchet-Noray L, et al
    Serum bilirubin levels and risk of colorectal cancer in Korean adults: results from the Korean Genome and Epidemiology Study-Health Examinee (KoGES-HEXA) Cohort Study.
    Br J Cancer. 2024 Oct 8. doi: 10.1038/s41416-024-02847.
    >> Share

  45. SEKHAR H, Kochhar R, Carrington B, Kaye T, et al
    Pre-treatment magnetic resonance imaging in anal cancer: large-scale evaluation of mrT, mrN and novel staging parameters.
    Br J Cancer. 2024;131:1137-1146.
    >> Share

    September 2024
  46. AMODIO V, Vitiello PP, Bardelli A, Germano G, et al
    DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors.
    Br J Cancer. 2024 Sep 13. doi: 10.1038/s41416-024-02848.
    >> Share

  47. BOLAND PM, Mukherjee S, Imanirad I, Vijayvergia N, et al
    TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial.
    Br J Cancer. 2024 Sep 7. doi: 10.1038/s41416-024-02845.
    >> Share

  48. CHOWDHURY S, Xiu J, Ribeiro JR, Nicolaides T, et al
    Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.
    Br J Cancer. 2024 Sep 4. doi: 10.1038/s41416-024-02826.
    >> Share

    August 2024
  49. GWENZI T, Schrotz-King P, Anker SC, Schottker B, et al
    Prognostic value of post-operative iron biomarkers in colorectal cancer: population-based patient cohort.
    Br J Cancer. 2024 Aug 27. doi: 10.1038/s41416-024-02814.
    >> Share

    July 2024
  50. SEGAL NH, Tie J, Kopetz S, Ducreux M, et al
    COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer.
    Br J Cancer. 2024 Jul 25. doi: 10.1038/s41416-024-02796.
    >> Share

  51. LAWLER T, Hibler E, Walts ZL, Giurini L, et al
    Associations of diabetes and mortality among colorectal cancer patients from the Southern Community Cohort Study.
    Br J Cancer. 2024 Jul 19. doi: 10.1038/s41416-024-02787.
    >> Share

  52. HOU P, Shi P, Jiang T, Yin H, et al
    Correction: DKC1 enhances angiogenesis by promoting HIF-1alpha transcription and facilitates metastasis in colorectal cancer.
    Br J Cancer. 2024 Jul 17. doi: 10.1038/s41416-024-02801.
    >> Share

  53. MASUI H, Kawada K, Itatani Y, Hirai H, et al
    Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on myeloid cells within the tumor microenvironment.
    Br J Cancer. 2024;131:63-76.
    >> Share

  54. TSUKADA Y, Bando H, Inamori K, Wakabayashi M, et al
    Three-year outcomes of preoperative chemoradiotherapy plus nivolumab in microsatellite stable and microsatellite instability-high locally advanced rectal cancer.
    Br J Cancer. 2024;131:283-289.
    >> Share

    June 2024
  55. YANG L, Yi J, He W, Kong P, et al
    Correction: Death receptors 4/5 mediate tumour sensitivity to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer.
    Br J Cancer. 2024 Jun 26. doi: 10.1038/s41416-024-02768.
    >> Share

  56. EXARCHAKOU A, Rachet B, Lyratzopoulos G, Maringe C, et al
    What can hospital emergency admissions prior to cancer diagnosis tell us about socio-economic inequalities in cancer diagnosis? Evidence from population-based data in England.
    Br J Cancer. 2024;130:1960-1968.
    >> Share

    May 2024
  57. YANG L, Yi J, He W, Kong P, et al
    Death receptors 4/5 mediate tumour sensitivitNot applicably to natural killer cell-mediated cytotoxicity in mismatch repair deficient colorectal cancer.
    Br J Cancer. 2024 May 25. doi: 10.1038/s41416-024-02673.
    >> Share

  58. ZWART K, van Nassau SCMW, van der Baan FH, Koopman M, et al
    Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab.
    Br J Cancer. 2024 May 20. doi: 10.1038/s41416-024-02711.
    >> Share

  59. VILLAREAL LB, Falcon DM, Xie L, Xue X, et al
    Hypoxia-inducible factor 3alpha1 increases epithelial-to-mesenchymal transition and iron uptake to drive colorectal cancer liver metastasis.
    Br J Cancer. 2024 May 1. doi: 10.1038/s41416-024-02699.
    >> Share

  60. QIAO L, Liu Y, Yang Q
    Comment on: "Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial".
    Br J Cancer. 2024;130:1432-1433.
    >> Share

  61. CAI J, Lin K, Luo T, Weng J, et al
    Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial.
    Br J Cancer. 2024;130:1434-1440.
    >> Share

  62. MENG XN, Ma JF, Liu YH, Li SQ, et al
    Dynamic genomic changes in methotrexate-resistant human cancer cell lines beyond DHFR amplification suggest potential new targets for preventing drug resistance.
    Br J Cancer. 2024;130:1819-1827.
    >> Share

  63. KISAKOL B, Matveeva A, Salvucci M, Kel A, et al
    Identification of unique rectal cancer-specific subtypes.
    Br J Cancer. 2024;130:1809-1818.
    >> Share

    April 2024
  64. REE AH, Saltyte Benth J, Hamre HM, Kersten C, et al
    First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial.
    Br J Cancer. 2024 Apr 25. doi: 10.1038/s41416-024-02696.
    >> Share

  65. RIO-VILARINO A, Cenigaonandia-Campillo A, Garcia-Bautista A, Mateos-Gomez PA, et al
    Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
    Br J Cancer. 2024 Apr 4. doi: 10.1038/s41416-024-02667.
    >> Share

  66. BARANYI M, Molnar E, Hegedus L, Gabriel Z, et al
    Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
    Br J Cancer. 2024;130:1059-1072.
    >> Share

  67. TIAN Y, Lin Y, Qu C, Arndt V, et al
    Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.
    Br J Cancer. 2024 Apr 1. doi: 10.1038/s41416-024-02638.
    >> Share

    March 2024
  68. FELIU J, Gamez-Pozo A, Martinez-Perez D, Perez-Wert P, et al
    Functional proteomics of colon cancer Consensus Molecular Subtypes.
    Br J Cancer. 2024 Mar 14. doi: 10.1038/s41416-024-02650.
    >> Share

  69. ZHANG X, He Y, Li X, Shraim R, et al
    Circulating 25-hydroxyvitamin D and survival outcomes of colorectal cancer: evidence from population-based prospective cohorts and Mendelian randomisation.
    Br J Cancer. 2024 Mar 13. doi: 10.1038/s41416-024-02643.
    >> Share

  70. RIO-VILARINO A, Cenigaonandia-Campillo A, Garcia-Bautista A, Mateos-Gomez PA, et al
    Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
    Br J Cancer. 2024 Mar 11. doi: 10.1038/s41416-024-02649.
    >> Share

  71. DENG LQ, Shi CJ, Zhou ST, Zeng WQ, et al
    EIF4A3-negatively driven circular RNA beta-catenin (circbeta-catenin) promotes colorectal cancer progression via miR-197-3p/CTNND1 regulatory axis.
    Br J Cancer. 2024 Mar 8. doi: 10.1038/s41416-024-02612.
    >> Share

  72. GOURIOU C, Lemanski C, Pommier P, Le Malicot K, et al
    Management of non-metastatic anal cancer in the elderly: ancillary study of the French multicenter prospective cohort FFCD-ANABASE.
    Br J Cancer. 2024;130:769-776.
    >> Share

    February 2024
  73. KARAPETIS CS, Liu H, Sorich MJ, Pederson LD, et al
    Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials fro
    Br J Cancer. 2024 Feb 24. doi: 10.1038/s41416-024-02604.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016